Aurora rejects Curaleaf's $260 million hostile bid as undervalued

Aurora Cannabis Inc.'s board on Sept 2 urged shareholders to reject Curaleaf Holdings Inc.'s unsolicited $260 million takeover bid, arguing the offer would let a buyer carrying more than $1 billion in debt take control of a debt-free rival holding $149 million in cash. The Edmonton-based medical cannabis firm filed a directors' circular recommending shareholders take no action and not tender their shares, and launched a ProtectAurora.com campaign to press its case.

"This transaction would be harmful to Aurora shareholders as the hostile bid is inadequate," Miguel Martin, executive chairman and chief executive officer of Aurora, said. "Curaleaf has over a $1 billion in debt and is asking shareholders to give up ownership of a stronger, debt-free and growing global medical cannabis company in exchange for an offer with intentionally limited upside."

The rejection rests on a sharp balance-sheet contrast. Aurora reported no debt and roughly $149 million in cash, restricted cash and short-term investments as of June 30, while Curaleaf carried more than $1 billion in indebtedness, financial obligations and lease liabilities on the same date, according to financial statements both companies filed Aug 5. Aurora's board, acting on the unanimous recommendation of a special committee of independent directors and a written opinion from its financial adviser dated Sept 1, also flagged that Aurora shareholders would own about 7.7 percent of a combined company but hold only roughly 3.2 percent of the votes because of Curaleaf's multi-voting share structure.

The fight now turns on whether Curaleaf sweetens its terms or presses ahead into a proxy contest. Curaleaf first proposed acquiring Aurora for $4.00 per share in mid-August, a price TD Securities said "undervalues Aurora and does not adequately reflect its medical cannabis leadership, balance sheet flexibility, international expertise, or long-term growth potential." Curaleaf shares closed at 13.66 Canadian dollars on Sept 1, up 1.94 percent, giving the buyer a market value of about 2.6 billion Canadian dollars, while Aurora traded at 5.60 Canadian dollars with a market capitalization near 261 million Canadian dollars.

Aurora argues its standalone plan offers more value than the bid. The company has spent years exiting lower-margin businesses and expanding EU-GMP cultivation and manufacturing capacity, a platform it says is difficult and expensive to replicate, and it recently announced accretive acquisitions of Internode Pharma Ltd. and HAP Pharma Ltd. to widen distribution in the UK medical market. Aurora's board said it is actively evaluating alternatives to the hostile bid, and shareholders who have already tendered were told to withdraw their shares through broker Kingsdale Advisors.

The outcome carries wider implications for cannabis-sector consolidation. If Curaleaf, the larger U.S.-focused operator, fails to win Aurora at its current price, it may be forced to raise its offer or walk away, while a successful bid would set a valuation benchmark for other debt-laden buyers eyeing cash-rich, debt-free targets. Aurora's board has signaled it will not accept a deal that transfers its cash to fix Curaleaf's balance sheet, setting up a standoff that could extend into a formal proxy fight if Curaleaf refuses to improve its terms.

This article is for informational purposes only and does not constitute investment advice.